An Extended Access Program for Bardoxolone Methyl in Patients With CKD (EAGLE)
Summary
- Eligibility
- for people ages 12 years and up (full criteria)
- Location
- at San Francisco, California and other locations
- Dates
- study startedestimated completion
- Principal Investigator
- by Meyeon Park, MD
Description
Summary
Official Title
Keywords
Eligibility
Locations
Lead Scientist at UCSF
- Meyeon Park, MD
My research focuses on the early diagnosis of kidney hypoxia, injury, and disease and the influence of cardiovascular disease on kidney disease onset and progression. Clinically, I see patients with all manifestations of hypertension and kidney disease, with a special focus on patients with polycystic kidney disease.
Details
- Status
- accepting new patients
- Start Date
- Completion Date
- (estimated)
- Sponsor
- Reata Pharmaceuticals, Inc.
- ID
- NCT03749447
- Phase
- Phase 3 research study
- Study Type
- Interventional
- Participants
- Expecting 480 study participants
- Last Updated